



Lyon July 7<sup>th</sup>, 2025

## **Synergistic collaboration between Edelris and Trimera, a Curie.Bio portfolio company**

Trimera Bio, a Curie.Bio portfolio company, and Edelris, a leader in organic and medicinal chemistry services, unique chemical collections and AS-MS screening for drug discovery, are delighted to announce a strategic collaboration.

As part of this collaboration, Trimera Bio is gaining access to Edelris' newly-launched EdelREADY screening plates. EdelREADY provides companies with a rapid, flexible, and cost-effective way to sample Edelris' unique and diverse Keymical Space in their own labs, with compound libraries provided as conveniently preformatted ready-to-assay DMSO stock solutions in multiwell plates. This development will enable Trimera Bio to leverage the best scientific solutions to develop its therapies.

Together, Trimera Bio, Curie.Bio and Edelris are committed to fostering an environment conducive to scientific innovation. This collaboration will enable biotech founders to leverage cutting-edge chemical solutions, accelerating the development of new therapies that address critical health challenges.

Joseph Zolnerciks, PhD., Chief Business Officer at Edelris commented *"One of the key differentiators and strengths of Edelris is the unique and diverse natural product-inspired chemical library that we have built over the past 20 years through the dedication of our talented pool of medicinal and organic chemists. Together with the support and collaboration of our partners and collaborators, we have demonstrated the value that our Keymical Space brings in successfully navigating from target to lead compound, and we are excited to make this more easily accessible to clients by way of the new EdelREADY screening ready plates."*

**About Curie.Bio:** Curie.Bio was founded to discover and develop important new medicines. We do that by investing directly into existing companies, creating focused spinouts, and helping founders build companies from scratch. We've combined two businesses in our model: we act as both your drug discovery copilot & investor. We have a 90+ person team of drug hunters, drug makers, and operators supporting founders day-to-day to increase their chances of developing medicines. We help founders avoid critical mistakes and ensure they have the right plan, data, and story to retain ownership and control over their company. We've raised \$1.25B and invest through two funds: the Seed Fund and the Breakout Fund. The Seed Fund focuses on advancing therapies through preclinical milestones, such as achieving in vivo proof-of-concept or selecting a development candidate. The Breakout Fund focuses on advancing medicines through clinical trials to generate impactful human activity data.

**About Edelris:** Edelris has been relentlessly bringing creative solutions to clients and partners from drug discovery organizations for the past 20 years, with a clear focus on Hit generation and Hit-to-Lead optimization. Edelris has pioneered the value of 3D, natural product-inspired compound collections for HTS and FBLD (Keymical Collections™ and Fragments), and offers track-proven medicinal chemistry and synthesis of explorative chemical libraries. Further to this, Edelris differentiates itself with EDEN (the Edelris Discovery ENgine), which is based upon a 2-million proprietary compound collection (Keymical Space™) and AS-MS technologies. More info at [www.edelris.com](http://www.edelris.com).